Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2023.
Participants during the call will be:
- Mondher Mahjoubi, Chief Executive Officer
- Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development
- Sonia Quaratino, Executive Vice President, Chief Medical Officer
- Frédéric Lombard, Senior Vice President, Chief Financial Officer
| Details for the Third Quarter 2023 Business Update Virtual EventTuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ETThe live webcast will be available at the following link:https://events.q4inc.com/attendee/172996087Webcast participants can use the chat tool to ask written questions during the conference.Participants may also join via telephone to ask oral questions during the conference using the following registration link: https://registrations.events/direct/Q4E61217This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event. |
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Source link : https://www.businesswire.com/
